Pemphigus: Our Clinical Experiences and Treatment Alternatives in the Resistant Cases

Uzun S.

TURKDERM-ARCHIVES OF THE TURKISH DERMATOLOGY AND VENEROLOGY, vol.42, pp.10-12, 2008 (Journal Indexed in SCI) identifier

  • Publication Type: Article / Article
  • Volume: 42
  • Publication Date: 2008
  • Page Numbers: pp.10-12


Pemphigus is an autoimmune blistering disease affecting skin and mucous membranes which threatens the life. In our country it is the most common disease in this group. In our region, among the pemphigus cases, the most common variant is pemphigus vulgaris. Pemphigus vulgaris consists of the 80% of pemphigus cases and it occurs 10 times more than pemphigus foliaceus. Treatment of pemphigus is accepted as a miracle in clinical medicine. The disease, which had an almost always fatal outcome, had been turned to the disease which long-term remissions or "cure" can be achievable. However, in the past the cause of the death was the disease itself, nowadays, with decreasing frequency, all of the mortalities is due to the treatment side effects. In treatment of pemphigus which drug to use and when to use it has varieties according to the intended effect. Corticosteroids are the main treatment; besides IVIg, plasmapheresis or pulse steroid prefers to control the disease rapidly. Mainly immunosuppressive agents (azathioprine, methotrexate, cyclophosphamide, cyclosporine, and mycophenolate) besides gold, dapsone, antibiotics or rituximab are using for late-term effect and to reduce the corticosteroid requirement. (Turkderm 2008; 42 Suppl 1: 10-2)